Contineum Therapeutics, Inc. Cash Flow Statement

1Y3Y5Y7Y10YAll
Download Data
Cash Flow Statement Dec2023 Dec2024
Operating Activities
Net Income 22.72M-42.26M
Share-based Compensation 2.22M6.80M
Gains from Investment Securities 2.67M4.05M
Non-cash Items 14.89M2.11M
Cash from Operations 19.35M-32.84M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 2.67M3.94M
Amortization of Deferred Charges -0.20M
Depreciation & Amortization (CF) 0.20M0.30M
Change in Working Capital
Change in Account Payables 1.14M
Change in Accured Expenses 1.59M2.30M
Investing Activities
Capital Expenditures 0.41M0.51M
Sales of Property, Plant and Equipment 0.02M
Change in Acquisitions & Divestments 76.71M157.16M
Cash from Investing Activities -65.57M-69.74M
Financing Activities
Other financing activities 0.02M
Debt Issuance and Repayment
Long-Term Debt Repayments 3.75M
Change in Capital Stock
Shares Issued 0.16M108.21M
Shares Repurchased 0.03M
Preferred Shares Issued 60.14M
Misc.
Cash from Financing Activities 56.18M109.00M
Change in Cash 9.96M6.42M
Beginning Cash Balance 5.57M15.53M
Free Cash Flow 18.93M-33.36M
Net Cash Flow 9.96M6.42M